tradingkey.logo

Myriad Genetics Inc

MYGN
5.120USD
+0.020+0.39%
Handelsschluss 02/06, 16:00ETKurse um 15 Minuten verzögert
476.67MMarktkapitalisierung
VerlustKGV TTM

Myriad Genetics Inc

5.120
+0.020+0.39%

mehr Informationen über Myriad Genetics Inc Unternehmen

Myriad Genetics, Inc. is a genetic testing and precision medicine company. The Company develops and offers genetic tests that help assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties where genetic insights can significantly improve patient care and lower healthcare costs. The Company is focused on three key areas where it has specialized products, capabilities, and expertise: Oncology, Women's Health, and Mental Health. In oncology, it offers testing for patients who have cancer and companion diagnostic tests that work with corresponding drugs and treatments. It also offers the SneakPeek Early Gender DNA Test, which can reveal a baby's gender as early as six weeks into pregnancy. The Company’s testing products include MyRisk, BRACAnalysis, BRACAnalysis CDx, MyChoice CDx, Prolaris, Foresight, Prequel, Precis Tumor, Precise Liquid, SneakPeek and GeneSight, among others.

Myriad Genetics Inc Informationen

BörsenkürzelMYGN
Name des UnternehmensMyriad Genetics Inc
IPO-datumOct 06, 1995
CEORaha (Samraat S)
Anzahl der mitarbeiter2700
WertpapierartOrdinary Share
GeschäftsjahresendeOct 06
Addresse322 North 2200 West
StadtSALT LAKE CITY
BörseNASDAQ OMX - NASDAQ BASIC
LandUnited States of America
Postleitzahl84116
Telefon18015843600
Websitehttps://myriad.com/
BörsenkürzelMYGN
IPO-datumOct 06, 1995
CEORaha (Samraat S)

Führungskräfte von Myriad Genetics Inc

Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Brian Donnelly
Mr. Brian Donnelly
Chief Commercial Officer
Chief Commercial Officer
397.53K
+397534.00%
Mr. Mark S. Verratti
Mr. Mark S. Verratti
Chief Operating Officer and Chief Commercial Officer
Chief Operating Officer and Chief Commercial Officer
253.38K
+32810.00%
Dr. Lee Nisley Newcomer, M.D.
Dr. Lee Nisley Newcomer, M.D.
Independent Director
Independent Director
132.14K
+49796.00%
Ms. Margaret (Maggie) Ancona
Ms. Margaret (Maggie) Ancona
Senior Vice President, Chief of Staff
Senior Vice President, Chief of Staff
127.73K
-958.00%
Ms. Rashmi Kumar
Ms. Rashmi Kumar
Independent Director
Independent Director
127.19K
+49796.00%
Ms. Shereen Solaiman
Ms. Shereen Solaiman
Chief People Officer
Chief People Officer
110.96K
+55173.00%
Mr. Benjamin Richard (Ben) Wheeler
Mr. Benjamin Richard (Ben) Wheeler
Chief Financial Officer
Chief Financial Officer
97.62K
+4994.00%
Dr. Dale Muzzey
Dr. Dale Muzzey
Chief Scientific Officer
Chief Scientific Officer
69.16K
+23697.00%
Ms. S. Louise Phanstiel, CPA
Ms. S. Louise Phanstiel, CPA
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Dr. Heiner Dreismann, Ph.D.
Dr. Heiner Dreismann, Ph.D.
Independent Director
Independent Director
--
--
Mehr Anzeigen
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Brian Donnelly
Mr. Brian Donnelly
Chief Commercial Officer
Chief Commercial Officer
397.53K
+397534.00%
Mr. Mark S. Verratti
Mr. Mark S. Verratti
Chief Operating Officer and Chief Commercial Officer
Chief Operating Officer and Chief Commercial Officer
253.38K
+32810.00%
Dr. Lee Nisley Newcomer, M.D.
Dr. Lee Nisley Newcomer, M.D.
Independent Director
Independent Director
132.14K
+49796.00%
Ms. Margaret (Maggie) Ancona
Ms. Margaret (Maggie) Ancona
Senior Vice President, Chief of Staff
Senior Vice President, Chief of Staff
127.73K
-958.00%
Ms. Rashmi Kumar
Ms. Rashmi Kumar
Independent Director
Independent Director
127.19K
+49796.00%
Ms. Shereen Solaiman
Ms. Shereen Solaiman
Chief People Officer
Chief People Officer
110.96K
+55173.00%

Umsatzaufteilung

Währung: USDAktualisiert: Tue, Jan 6
Währung: USDAktualisiert: Tue, Jan 6
FY2025Q3
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2021
FY2020
Nach GeschäftsbereichUSD
Name
Umsatz
Anteil
Hereditary Cancer
93.00M
45.21%
Prenatal
44.50M
21.63%
Pharmacogenomics
38.70M
18.81%
Tumor Profiling
29.50M
14.34%
Nach RegionUSD
Name
Umsatz
Anteil
United States
191.70M
93.19%
Rest of world
14.00M
6.81%
Nach Geschäftsbereich
Nach Region
Nach GeschäftsbereichUSD
Name
Umsatz
Anteil
Hereditary Cancer
93.00M
45.21%
Prenatal
44.50M
21.63%
Pharmacogenomics
38.70M
18.81%
Tumor Profiling
29.50M
14.34%

Aktionärsstatistik

Aktualisiert: Tue, Nov 18
Aktualisiert: Tue, Nov 18
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
BlackRock Institutional Trust Company, N.A.
14.22%
The Vanguard Group, Inc.
8.71%
State Street Investment Management (US)
5.34%
Glenview Capital Management, LLC
5.30%
Millennium Management LLC
5.09%
Andere
61.34%
Aktionäre
Aktionäre
Anteil
BlackRock Institutional Trust Company, N.A.
14.22%
The Vanguard Group, Inc.
8.71%
State Street Investment Management (US)
5.34%
Glenview Capital Management, LLC
5.30%
Millennium Management LLC
5.09%
Andere
61.34%
Aktionärstypen
Aktionäre
Anteil
Investment Advisor
38.05%
Investment Advisor/Hedge Fund
27.93%
Hedge Fund
26.06%
Research Firm
5.93%
Individual Investor
3.30%
Pension Fund
1.72%
Bank and Trust
0.43%
Family Office
0.24%
Sovereign Wealth Fund
0.04%

Institutionelle Beteiligung

Aktualisiert: Thu, Jan 1
Aktualisiert: Thu, Jan 1
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q4
534
92.66M
99.41%
-13.08M
2025Q3
518
92.00M
98.69%
-11.12M
2025Q2
518
100.80M
108.34%
-1.85M
2025Q1
527
99.14M
107.57%
-4.54M
2024Q4
516
96.89M
106.12%
-1.41M
2024Q3
505
95.02M
104.61%
-5.50M
2024Q2
486
96.79M
106.52%
-6.22M
2024Q1
460
98.19M
108.68%
+613.48K
2023Q4
464
93.46M
105.77%
+2.70M
2023Q3
471
86.01M
104.78%
-3.73M
Mehr Anzeigen

Aktionärsaktivitäten

Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
BlackRock Institutional Trust Company, N.A.
13.25M
14.22%
-176.76K
-1.32%
Sep 30, 2025
The Vanguard Group, Inc.
7.77M
8.34%
-1.37M
-15.03%
Sep 30, 2025
State Street Investment Management (US)
4.98M
5.34%
+166.54K
+3.46%
Sep 30, 2025
Glenview Capital Management, LLC
4.59M
4.92%
--
--
Sep 30, 2025
Millennium Management LLC
4.75M
5.09%
-176.39K
-3.58%
Sep 30, 2025
D. E. Shaw & Co., L.P.
4.56M
4.89%
+47.64K
+1.06%
Sep 30, 2025
Morgan Stanley & Co. LLC
2.49M
2.67%
-883.07K
-26.17%
Sep 30, 2025
Jacobs Levy Equity Management, Inc.
2.44M
2.62%
+1.49M
+157.01%
Sep 30, 2025
Geode Capital Management, L.L.C.
2.23M
2.39%
+2.21K
+0.10%
Sep 30, 2025
Camber Capital Management LP
2.00M
2.15%
-350.00K
-14.89%
Jun 30, 2025
Mehr Anzeigen

Verbundene ETFs

Aktualisiert: Sat, Dec 6
Aktualisiert: Sat, Dec 6
Name
Anteil
Global X Genomics & Biotechnology ETF
0.8%
Invesco NASDAQ Future Gen 200 ETF
0.68%
Federated Hermes MDT Small Cap Core ETF
0.5%
Invesco S&P SmallCap Health Care ETF
0.46%
State Street SPDR S&P Biotech ETF
0.24%
Strategas Global Policy Opportunities ETF
0.22%
Inspire Small/Mid Cap ESG ETF
0.22%
Direxion Daily S&P Biotech Bull 3X Shares
0.14%
Vanguard US Quality Factor ETF
0.14%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
0.12%
Mehr Anzeigen
Global X Genomics & Biotechnology ETF
Anteil0.8%
Invesco NASDAQ Future Gen 200 ETF
Anteil0.68%
Federated Hermes MDT Small Cap Core ETF
Anteil0.5%
Invesco S&P SmallCap Health Care ETF
Anteil0.46%
State Street SPDR S&P Biotech ETF
Anteil0.24%
Strategas Global Policy Opportunities ETF
Anteil0.22%
Inspire Small/Mid Cap ESG ETF
Anteil0.22%
Direxion Daily S&P Biotech Bull 3X Shares
Anteil0.14%
Vanguard US Quality Factor ETF
Anteil0.14%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
Anteil0.12%

Dividende

In den vergangenen 5 Jahren wurden insgesamt 0.00 USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten

Aktien-Split

Datum
Ex-Dividendentag
Art
Verhältnis
Keine Daten
Datum
Ex-Dividendentag
Art
Verhältnis
Keine Daten
KeyAI